Attention Deficit Hyperactivity Disorder Market - Emerging Trends And The Role Of Regulatory Frameworks

Attention Deficit Hyperactivity Disorder Industry Overview

The global attention deficit hyperactivity disorder market size was estimated at USD 14.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2030. The market's growth can be attributed to the escalating demand for attention deficit hyperactivity disorder (ADHD) drugs, driven by the rising global prevalence of ADHD. This growth is further fueled by the increasing awareness about the disorder among healthcare professionals and patients, as well as the escalating healthcare expenditure across various regions.

Gather more insights about the market drivers, restrains and growth of the Attention Deficit Hyperactivity Disorder Market

The prevalence of ADHD in children has been linked to reduced health and well-being for patients and their families. As a common neurological developmental disorder, ADHD is increasingly recognized in adolescents, adults, and children. According to a study published in the Italian Journal of Pediatrics in 2023, the global prevalence of ADHD in children aged 3 to 12 years is 7.6%, while it is 5.6% for those aged 12 to 18 years. The Forbes Health Report of 2023 indicates that approximately 129 million adolescents and children between 5 to 19 years old are living with ADHD. Consequently, the rising prevalence of ADHD is expected to drive the demand for medications used in its treatment.

The growing awareness of ADHD among patients, healthcare professionals, and other medical practitioners is expected to stimulate the diagnosis and treatment of the condition, propelling market growth. Enhanced understanding of ADHD is expected to contribute to improved academic outcomes for students affected by the disorder. In an effort to advance treatment quality for children with ADHD, the National Institute for Children's Health Quality has implemented a collaborative model in partnership with children and adults with Attention-Deficit/Hyperactivity Disorder (CHADD) and the American Academy of Pediatrics (AAP).

In addition to the efforts of the National Institute for Children's Health Quality, organizations such as the ADHD Coaches Organization (ACO), Attention Deficit Disorder Association (ADDA), and CHADD are proactively working to raise awareness about ADHD and available treatment options globally through various campaigns. For instance, in 2022, these organizations organized a program called "Reframing ADHD: Discovering New Perspectives," that aimed to address aspects including ADHD relationships and communications, diagnosis in children and adults, treatment plans, and co-occurring situations.

October is recognized worldwide as ADHD Awareness Month, dedicated to increasing understanding and educating people about ADHD. According to CHADD, the healthcare costs associated with treating ADHD in adults aged 18 to 64 range from USD 137 to USD 4,100 per person annually. Consequently, the growing financial burden has led to a heightened need for evaluating efficient, low-cost treatment options for ADHD that significantly contribute to market growth.

Order a free sample PDF of the Attention Deficit Hyperactivity Disorder Market Intelligence Study, published by Grand View Research.

Key Companies profiled:

• Eli Lilly and Company.

• Pfizer Inc.

• Johnson & Johnson Services Inc.

• Lupin

• Novartis AG

• Takeda Pharmaceutical Company Limited

• Mallinckrodt Inc.

• Purdue Pharma LP

• NEOS Therapeutics Inc.

• Supernus Pharmaceutical, Inc.

Key Attention Deficit Hyperactivity Disorder Company Insights

• Novartis AG, a global pharmaceutical company, offers various brands for the treatment of attention deficit hyperactivity disorder. Some of the notable Novartis AG brands for ADHD include Ritalin, Concerta, Adderall, Vyvanse, and Strattera.

• Eli Lilly and Company, a multinational pharmaceutical corporation, also offers a variety of brands for the management of attention deficit hyperactivity disorder. The Eli Lilly and Company brands for ADHD include Adderall XR and QuilliChew ER.

Recent Developments

• In July 2022, Swedish pharmaceutical company AGB-Pharma introduced Adaflex, the first melatonin product in the UK designed for insomnia in children and adolescents aged 6 to 17 years with ADHD when conventional sleep hygiene measures prove insufficient.

• In April 2022, Supernus Pharmaceuticals, Inc. received FDA approval for Qelbree, developed by Supernus Pharmaceuticals, Inc., for treating ADHD patients aged 18 years and above. This approval was anticipated to increase the consumer base for the product.